Increasing Chemotherapy Dose Density and Intensity: Phase I Trials in Non‐Small Cell Lung Cancer and Non‐Hodgkin's Lymphoma

• Published in: The oncologist (Dayton, Ohio) Ohio), 2005-02, Vol.10 (2), p.138-149
• Main Authors: Blayney, Douglas W., McGuire, Brian W., Cruickshank, Scott E., Johnson, David H.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma, Non-Small-Cell Lung - drug therapy; Chemotherapy; Cisplatin - administration & dosage; Cisplatin - adverse effects; Cyclophosphamide - administration & dosage; Cyclophosphamide - adverse effects; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Drug dose‐response relationships; Etoposide - administration & dosage; Etoposide - adverse effects; Female; Filgrastim; Granulocyte Colony-Stimulating Factor - administration & dosage; Humans; Lung Neoplasms - drug therapy; Lymphoma, Non-Hodgkin - drug therapy; Male; Middle Aged; Neoplasm Staging; Neutropenia; Neutropenia - chemically induced; Non‐Hodgkin's lymphoma; Non‐small cell lung carcinoma; Prednisone - administration & dosage; Prednisone - adverse effects; Recombinant Proteins; Thrombocytopenia - chemically induced; Treatment Outcome; Vincristine - administration & dosage; Vincristine - adverse effects
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1634/theoncologist.10-2-138

Dose densification and dose escalation of cytotoxic chemotherapy may be important in improving the cure rates of chemotherapy‐responsive cancers. We conducted two phase I studies, in non‐small cell lung cancer (NSCLC) and in lymphoma, to explore the possibility of intensifying chemotherapy by compressing the delivery of and escalating the dose of standard combination chemotherapy. One study used etoposide and cisplatin chemotherapy in patients with unresectable stage III or IV NSCLC, intensifying chemotherapy by reducing the cycle length. The second study used cyclophosphamide, doxorubicin, vincristine, and prednisone, CHOP chemotherapy, in the treatment of stage II–IV intermediate or immunoblastic high‐grade lymphoma, intensifying chemotherapy first by reducing the cycle length and then by escalating the dosages of cyclophosphamide and doxorubicin. Filgrastim support was used during dose intensification. Fifty‐five patients with NSCLC and 49 with non‐Hodgkin's lymphoma (NHL) were enrolled and treated in successive cohorts. At standard dosages and intervals of chemotherapy, filgrastim support resulted in incidences of grade 3 and 4 neutropenia that were between 62% and 77% lower than those in the no‐filgrastim control; the mean duration of neutropenia was, likewise, more than 80% lower. Absolute neutrophil counts were ≥2 × 109/l at day 14 in virtually 100% of patients receiving filgrastim. In the NSCLC trial, etoposide and cisplatin were intensified by >50%, and in the lymphoma trial, cyclophosphamide was intensified by 270% and doxorubicin was intensified by 87%. Chemotherapy reductions or delays for neutropenia were rare in the groups receiving filgrastim; but at higher chemotherapy intensities, dose‐limiting thrombocytopenia was encountered. We conclude that the delivery of myelosuppressive chemotherapy in both a dose‐intense and a dose‐dense manner is feasible with filgrastim support.